Atopic dermatitis (AD), also known as eczema, is a common skin disorder. Symptoms can include flaky skin lesions and intense itching. An estimated 10% of adults and up to 20% of children suffer from AD. AD can unpredictably flare in adolescence and in adulthood.
People with mild or moderate atopic dermatitis (a.k.a. eczema) may be eligible to join this research study of an investigational medication for the condition. Eligible participants will receive compensation for study-related time and travel, as well as study-related exams at no cost.
- Must be age 18 to 75
- Must have been diagnosed with chronic eczema for at least six months
- May receive compensation for study-related time and travel
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.
Submit your information
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.